# France Vasomotor Symptoms Market > France Vasomotor Symptoms Market Research Report By Therapy Type (Hormonal, Non-Hormonal) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.58% - **2024:** $ 100.5 Million - **2025:** $ 107.11 Million - **2035:** $ 202.5 Million - **Key Players:** Pfizer Inc (US), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Hoffmann-La Roche Ltd (CH), AstraZeneca PLC (GB), Novartis AG (CH) **Report ID:** MRFR/HC/49993-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/france-vasomotor-symptoms-market-51751 --- ## Market Summary ## **France Vasomotor Symptoms Market Overview** As per MRFR analysis, the France Vasomotor Symptoms Market Size was estimated at 169.2 (USD Million) in 2023.The France Vasomotor Symptoms Market Industry is expected to grow from 180.9(USD Million) in 2024 to 569.4 (USD Million) by 2035. The France Vasomotor Symptoms Market CAGR (growth rate) is expected to be around 10.987% during the forecast period (2025 - 2035) **Key France Vasomotor Symptoms Market Trends Highlighted** The France Vasomotor Symptoms Market exhibits several important trends influenced by various factors. One of the key market drivers is the aging population in France, which has led to an increased prevalence of conditions like menopause that cause vasomotor symptoms. Additionally, the growing awareness and acceptance of women's health issues have led to higher demand for effective treatment options, spurring innovation in pharmaceuticals and alternative therapies.  France’s healthcare system emphasizes the importance of personalized care, which presents significant opportunities for tailored treatment plans to address vasomotor symptoms more effectively.Recent trends indicate a shift toward a holistic approach to managing vasomotor symptoms.  This includes not only the traditional hormone replacement therapies but also lifestyle changes and complementary therapies, gaining traction among healthcare providers and patients. The development of natural and herbal remedies, in response to concerns over the side effects of hormonal treatments, is also becoming prominent in the French market. Moreover, the advancement of digital health technologies is shaping the landscape of management strategies for vasomotor symptoms.  Patients in France are increasingly leveraging telehealth services for consultations and remote monitoring, facilitating better access to healthcare professionals and customized treatment options.This trend is likely to grow further as France continues to enhance its digital health infrastructure, aiming to provide better support and resources for women facing these symptoms.  In summary, the France Vasomotor Symptoms Market is characterized by a growing focus on women’s health, increasing personalization of treatments, and the integration of technology into healthcare delivery, providing numerous opportunities and challenges for stakeholders in the field. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **France Vasomotor Symptoms Market Drivers** **Increasing Prevalence of Menopausal Women** The France Vasomotor Symptoms Market Industry is driven mostly by the country's increasing number of women entering the menopausal period. According to statistics, the number of women over 50 is expected to rise, and during this time, about 35% of them may have vasomotor symptoms, including hot flashes and night sweats. The French National Institute of Statistics and Economic Studies (INSEE) projects that this population will grow dramatically, increasing the need for efficient therapies. Additionally, the cooperation of groups such as the French Society of Menopause encourages awareness and conversation about these symptoms, which raises the market's profile and demand for treatment alternatives.  The healthcare sector is anticipated to develop and broaden its product offerings in response to the increasing number of women seeking relief from the discomfort brought on by hormonal fluctuations, which will eventually aid in market expansion. This pattern highlights how urgently this particular population needs specialised treatments and healthcare plans. **Rising Awareness and Acceptance of Hormone Replacement Therapy** The increasing acceptance and advocacy for Hormone Replacement Therapy (HRT) among women experiencing vasomotor symptoms drive market growth in France. HRT has been shown to alleviate symptoms significantly, and recent educational campaigns initiated by healthcare professionals and women's health organizations in France have improved awareness regarding its benefits.  The French National Health Authority has been involved in disseminating information about HRT, addressing concerns regarding safety, and highlighting its effectiveness.In recent years, the usage of HRT has seen a resurgence, with a reported 15% increase in prescriptions among menopausal women in France. This acceptance shifts public perception positively toward treatment options and enhances market prospects in the France Vasomotor Symptoms Market Industry. **Technological Advancements in Treatment Options** Innovation in pharmaceuticals and treatment modalities for vasomotor symptoms propels the France Vasomotor Symptoms Market Industry forward. Recent developments include the introduction of new non-hormonal medications and delivery methods, enhancing treatment effectiveness and patient compliance. For instance, clinical trials conducted by leading pharmaceutical companies in France have led to the development of medications like a new non-hormonal oral treatment that has demonstrated efficacy in reducing hot flashes in clinical studies. According to the French Medicines Agency, the approval of these advanced treatments is on the rise, with a reported 25% increase in novel treatment approvals in the last five years. This technological evolution responds to patient needs for safer and more effective options, stimulating market growth and providing new avenues for addressing vasomotor symptoms. **France Vasomotor Symptoms Market Segment Insights** **Vasomotor Symptoms Market Therapy Type Insights** The France Vasomotor Symptoms Market, specifically focusing on the Therapy Type segment, encompasses a diverse range of treatment options primarily categorized into Hormonal and Non-Hormonal therapies. Hormonal therapies have traditionally dominated this market segment, being favored for their effectiveness in alleviating symptoms such as hot flashes and night sweats experienced during menopause. The utilization of estrogen and progesterone has undeniable historical significance, as regulatory bodies in France have advocated for their applications, resulting in substantial patient acceptance.  However, there is a growing awareness of the associated risks tied to hormonal therapies, which has prompted a significant shift towards Non-Hormonal alternatives, making it a vital area of growth within the market. Non-Hormonal therapies are gaining traction due to their favorable safety profile and accessibility, particularly among women who may not be suitable candidates for Hormonal treatments.  This category includes options such as selective serotonin reuptake inhibitors (SSRIs), supplements like soy isoflavones, and lifestyle interventions. The increased emphasis on personalized healthcare has led to a more informed consumer base in France, keen on exploring diverse treatment modalities that address their specific health concerns without the complications that may arise from Hormonal therapies.  As patients become more educated about their options, the demand for Non-Hormonal treatments continues to escalate, driving innovation and research in the sector. Factors such as cultural shifts towards holistic health practices, as well as the growing body of evidence supporting the efficacy of Non-Hormonal therapies, are likely to spur further development. The rising incidence of menopause-related symptoms, fuelled by demographic trends in France, indicates a robust market opportunity for both therapy types. Continued advancements in the formulation of Non-Hormonal treatments may enhance acceptance and market penetration.  Moreover, the French healthcare system's commitment to patient education, coupled with initiatives by health organizations to raise awareness about the implications of various treatment options, is crucial in influencing therapy selection. Overall, the France Vasomotor Symptoms Market's Therapy Type segment reflects a dynamic landscape where Hormonal and Non-Hormonal treatments coexist, each adapting to the evolving needs and preferences of women experiencing vasomotor symptoms. This trend points towards a balanced approach in treatment that respects individual patient choices and needs. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Vasomotor Symptoms Market Distribution Channel Insights** The France Vasomotor Symptoms Market is witnessing significant growth across its Distribution Channel segment, showcasing various avenues for accessing critical treatments. Hospital pharmacies play a vital role by providing immediate access to medications for inpatients and emergency cases, thereby ensuring prompt care for individuals experiencing vasomotor symptoms. Retail pharmacies, on the other hand, are essential for community-based care, catering to outpatient needs and offering personalized consultations for product selection. They foster relationships with local patients, enhancing adherence to treatments. Meanwhile, the rise of online stores is revolutionizing the market by providing easy access to medications from the comfort of home, particularly appealing during times of heightened health concerns. This growing trend is largely driven by increased internet penetration and a shift towards e-commerce, allowing consumers to compare products and prices easily. With the increasing awareness of vasomotor symptoms and the broadening array of treatments available, the Distribution Channel for the France Vasomotor Symptoms Market is critical in ensuring that patients can access these therapies conveniently and effectively, reflecting the need for a multi-channel approach to healthcare delivery.The interplay between these channels is expected to shape the future landscape of this market segment, highlighting its importance in addressing the needs of patients across France. **France Vasomotor Symptoms Market Key Players and Competitive Insights** The France Vasomotor Symptoms Market is characterized by a competitive landscape marked by the presence of established pharmaceutical companies, innovative therapeutic approaches, and evolving consumer preferences. As the awareness around menopause and related symptoms broadens, the demand for effective treatments continues to rise, prompting companies to enhance their product offerings and expand their market reach. In this environment, players are not only focusing on traditional therapies but are also exploring novel solutions that cater to the complex needs of women experiencing vasomotor symptoms.  The competitive insights reflect ongoing trends such as collaboration, research and development, and strategic partnerships aimed at increasing market share while improving patient outcomes and satisfaction.Johnson & Johnson has a significant presence in the France Vasomotor Symptoms Market, leveraging its strong brand reputation and established distribution channels to ensure accessibility of its products. The company has successfully positioned itself through a robust portfolio of solutions that address the needs of women dealing with menopausal symptoms, which includes vasomotor issues such as hot flashes and night sweats.  The strengths of Johnson & Johnson lie in its commitment to research and development, allowing it to continuously innovate and provide high-quality therapies. Moreover, its strategic marketing strategies and patient education initiatives enable better awareness and acceptance of its products among healthcare professionals and end-users alike.Teva Pharmaceutical Industries has also carved out a notable presence in the France Vasomotor Symptoms Market, focusing on generic and specialty medicines that cater to this demographic. The company offers a range of therapeutic options that address vasomotor symptoms, enhancing patient choice and affordability.  Teva’s strengths in the French market are bolstered by its extensive experience in pharmacology and a commitment to developing innovative therapies that are safe and effective. The company has pursued strategic acquisitions and partnerships that broaden its product line and facilitate access to advanced treatment options for menopausal symptoms. Through these efforts, Teva continues to enhance its competitive edge, ensuring that it remains a key player in meeting the evolving needs of women experiencing vasomotor symptoms in France. **Key Companies in the France Vasomotor Symptoms Market Include** **France Vasomotor Symptoms Market Industry Developments** In recent developments, the France Vasomotor Symptoms Market has seen a significant growth trajectory, driven by increased awareness and advancements in treatment options. Companies like Johnson and Johnson, Teva Pharmaceutical Industries, and GSK have been at the forefront of introducing innovative therapies aiming to alleviate symptoms associated with menopause. In September 2023, Merck announced an expansion of their product line tailored for treating vasomotor symptoms, enhancing their position in the market. Meanwhile, in July 2023, Novartis launched a new clinical trial in metropolitan France focused on their latest investigational drug, with preliminary results indicating promising efficacy.  Mergers and acquisitions have also played a role, as Eli Lilly acquired a niche therapy startup in August 2023, aiming to complement their offerings in the vasomotor symptoms space. Growth in market valuation for major players, including AbbVie and Pfizer, has been linked to an increasing aging population in France, which requires comprehensive management of vasomotor symptoms. Furthermore, GSK and Takeda Pharmaceutical are collaborating on Research and Development initiatives for groundbreaking treatments catering specifically to the needs of female patients in France, reflecting the dynamic nature of this sector in the region. **France Vasomotor Symptoms Market Segmentation Insights** ## Market Drivers ### Advancements in Pharmaceutical Research Recent advancements in pharmaceutical research are likely to play a crucial role in shaping the vasomotor symptoms market. Innovative drug formulations and delivery systems are being developed to enhance the efficacy and safety of treatments for vasomotor symptoms. For instance, the introduction of bioidentical hormone therapies and non-hormonal alternatives may provide women with more options tailored to their specific needs. The French pharmaceutical industry has invested heavily in research and development, with expenditures reaching €5 billion in 2025. This investment is expected to yield new therapies that could significantly impact the vasomotor symptoms market, offering improved outcomes for patients. ### Increasing Awareness of Menopausal Health The growing awareness surrounding menopausal health in France appears to be a significant driver for the vasomotor symptoms market. As more women become informed about the symptoms associated with menopause, including hot flashes and night sweats, there is a rising demand for effective treatments. Educational campaigns and healthcare initiatives are likely contributing to this trend, as they encourage women to seek medical advice and explore available options. This heightened awareness may lead to an increase in consultations with healthcare professionals, thereby expanding the market for therapies aimed at alleviating vasomotor symptoms. In 2025, it is estimated that approximately 50% of women in France will experience these symptoms, further underscoring the need for targeted solutions in the vasomotor symptoms market. ### Regulatory Support for Innovative Therapies Regulatory support for innovative therapies in France is likely to enhance the growth of the vasomotor symptoms market. The French government has been actively promoting the development and approval of new treatments, particularly those that demonstrate safety and efficacy. Initiatives aimed at expediting the approval process for novel therapies may encourage pharmaceutical companies to invest in research and development. This regulatory environment could lead to a wider array of treatment options for women experiencing vasomotor symptoms. In 2025, it is anticipated that the number of approved therapies in this market will increase by 20%, reflecting the positive impact of regulatory support on innovation. ### Aging Population and Increased Life Expectancy The aging population in France is a critical driver for the vasomotor symptoms market. As life expectancy continues to rise, a larger segment of the population is entering menopause, which is associated with various vasomotor symptoms. By 2025, it is projected that over 15 million women in France will be in the menopausal age group, leading to a corresponding increase in demand for effective treatments. This demographic shift suggests that healthcare providers will need to adapt their services to address the specific needs of older women, thereby expanding the vasomotor symptoms market. The implications of an aging population are profound, as they necessitate a reevaluation of healthcare strategies to ensure adequate support for this demographic. ### Integration of Holistic Approaches in Treatment The integration of holistic approaches in the treatment of vasomotor symptoms is emerging as a notable trend in France. Many healthcare providers are recognizing the importance of addressing not only the physical but also the emotional and psychological aspects of menopause. This shift towards a more comprehensive treatment model may include lifestyle modifications, dietary changes, and alternative therapies such as acupuncture and mindfulness practices. As patients increasingly seek holistic solutions, the vasomotor symptoms market is likely to expand to accommodate these preferences. By 2025, it is expected that around 30% of women will opt for complementary therapies alongside conventional treatments, indicating a significant shift in treatment paradigms. ## Future Outlook The [Vasomotor Symptoms Market](https://www.marketresearchfuture.com/reports/vasomotor-symptoms-market-9810) is projected to grow at a 6.58% CAGR from 2025 to 2035, driven by increasing awareness and innovative treatment options. **New opportunities:** - Development of telehealth platforms for remote consultations - Investment in personalized hormone therapy solutions - Expansion of over-the-counter treatment options for self-management By 2035, the market is expected to achieve substantial growth, reflecting evolving consumer needs and treatment advancements. ## Segment Insights ### By Type: Hormonal (Largest) vs. Non-Hormonal (Fastest-Growing) The distribution of market share among segment values within the France vasomotor symptoms market reveals that the Hormonal segment currently holds the largest share, driven by established therapies and a strong market presence. In contrast, the Non-Hormonal segment is gaining traction, appealing particularly to consumers seeking alternatives due to concerns over hormone-related side effects. Growth trends indicate a significant rise in the demand for Non-Hormonal therapies, attributed to the increasing awareness of hormone therapy risks and growing preference for natural solutions. As healthcare practitioners endorse tailored treatments, the Non-Hormonal segment is projected to experience the fastest growth, reflecting shifting consumer attitudes and enhanced product innovation in this area. Treatment Type: Hormonal (Dominant) vs. Non-Hormonal (Emerging) The Hormonal segment is characterized by its dominance in the France vasomotor symptoms market, offering well-established treatments that have proven effective over time. These therapies often include a wide range of hormone replacements that target menopausal symptoms, leading to consumer trust and sustained market presence. On the other hand, the Non-Hormonal segment is emerging as a notable alternative, focusing on natural and plant-based treatments that are appealing to a growing demographic concerned about the side effects of hormonal therapies. This shift towards non-invasive treatment options reflects broader health trends, and as new products enter the market, the Non-Hormonal segment is likely to expand rapidly, attracting both new and existing consumers. ### By Distribution Channel: Retail Pharmacies (Largest) vs. Online Stores (Fastest-Growing) In the France vasomotor symptoms market, the distribution of market share among various channels reveals that hospital pharmacies hold a significant position, yet retail pharmacies are leading as the largest channel. They dominate sales due to their widespread accessibility and established customer bases. Online stores, while currently smaller in share, represent an emerging segment rapidly gaining traction, especially among younger demographics who prefer online shopping for health-related products. The growth trends in this segment are driven by the increasing shift towards digitalization and the convenience offered by online platforms. The pandemic has accelerated the adoption of online purchases, pushing retailers to enhance their online presence and offerings. Additionally, the reliability and trust in retail pharmacies continue to solidify their market position, while online stores innovate with services like home delivery and subscription models, appealing to consumers seeking ease of access and variety. Retail Pharmacies (Dominant) vs. Online Stores (Emerging) Retail pharmacies are the dominant force in the distribution channel segment due to their established infrastructure and strong customer relationships. They serve as a critical point for patients seeking immediate relief from vasomotor symptoms, offering personalized advice and a range of products. This face-to-face interaction builds trust among consumers. In contrast, online stores are positioned as an emerging channel, leveraging technology to provide convenience and wider access to treatment options. They appeal particularly to tech-savvy customers who value privacy and the ability to compare products before purchase. The growth of online pharmacies signifies a shift in consumer behavior, where the convenience of home delivery and competitive pricing are becoming increasingly appealing. ## Competitive Benchmarking The vasomotor symptoms market in France is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Pfizer Inc (US), AbbVie Inc (US), and Hoffmann-La Roche Ltd (CH) are actively engaged in enhancing their product offerings and expanding their market presence. Pfizer Inc (US) has positioned itself as a leader in the development of novel therapies aimed at alleviating vasomotor symptoms, leveraging its robust R&D capabilities to introduce innovative solutions that cater to the evolving needs of patients. Meanwhile, AbbVie Inc (US) has been focusing on strategic acquisitions to bolster its portfolio, thereby enhancing its competitive edge in this niche market. Hoffmann-La Roche Ltd (CH) is also making strides through partnerships aimed at integrating digital health solutions into its therapeutic offerings, reflecting a broader trend towards technology-driven healthcare solutions.The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players vying for market share. However, the collective influence of these key players is significant, as they drive innovation and set industry standards that smaller companies often follow. In October Pfizer Inc (US) announced a collaboration with a leading digital health company to develop a mobile application designed to support patients managing vasomotor symptoms. This strategic move is likely to enhance patient engagement and adherence to treatment regimens, thereby improving overall health outcomes. The integration of digital tools into traditional therapies may also provide Pfizer with a competitive advantage in a market that increasingly values technology-driven solutions. In September AbbVie Inc (US) completed the acquisition of a biotech firm specializing in hormone therapies, which is expected to expand its product pipeline significantly. This acquisition not only strengthens AbbVie's position in the vasomotor symptoms market but also aligns with its strategy to diversify its offerings and enhance its therapeutic capabilities. The move suggests a commitment to addressing unmet medical needs in this area, potentially leading to increased market share. In August Hoffmann-La Roche Ltd (CH) launched a new clinical trial aimed at evaluating the efficacy of a combination therapy for vasomotor symptoms. This initiative underscores the company's focus on evidence-based approaches to treatment and its commitment to advancing scientific knowledge in the field. The outcomes of this trial could have far-reaching implications for treatment protocols and patient care standards. As of November the competitive trends in the vasomotor symptoms market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into healthcare solutions. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing the development of patient-centric therapies. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, reflecting a broader shift in the pharmaceutical industry towards value-based care. ## Recent News & Developments In recent developments, the France Vasomotor Symptoms Market has seen a significant growth trajectory, driven by increased awareness and advancements in treatment options. Companies like Johnson and Johnson, Teva Pharmaceutical Industries, and GSK have been at the forefront of introducing innovative therapies aiming to alleviate symptoms associated with menopause. In September 2023, Merck announced an expansion of their product line tailored for treating vasomotor symptoms, enhancing their position in the market. Meanwhile, in July 2023, Novartis launched a new clinical trial in metropolitan France focused on their latest investigational drug, with preliminary results indicating promising efficacy.  Mergers and acquisitions have also played a role, as Eli Lilly acquired a niche therapy startup in August 2023, aiming to complement their offerings in the vasomotor symptoms space. Growth in market valuation for major players, including AbbVie and Pfizer, has been linked to an increasing aging population in France, which requires comprehensive management of vasomotor symptoms. Furthermore, GSK and Takeda Pharmaceutical are collaborating on Research and Development initiatives for groundbreaking treatments catering specifically to the needs of female patients in France, reflecting the dynamic nature of this sector in the region. ## Report Scope | MARKET SIZE 2024 | 100.5(USD Million) | | --- | --- | | MARKET SIZE 2025 | 107.11(USD Million) | | MARKET SIZE 2035 | 202.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.58% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer Inc (US), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Hoffmann-La Roche Ltd (CH), AstraZeneca PLC (GB), Novartis AG (CH) | | Segments Covered | Type, Distribution Channel | | Key Market Opportunities | Emerging therapies targeting hormonal balance present opportunities in the vasomotor symptoms market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition in the vasomotor symptoms market amid evolving regulatory frameworks. | | Countries Covered | France | ## Frequently Asked Questions **Q: What was the market valuation for vasomotor symptoms in France in 2024?** A: The market valuation for vasomotor symptoms in France was $100.5 Million in 2024. **Q: What is the projected market valuation for vasomotor symptoms in France by 2035?** A: The projected market valuation for vasomotor symptoms in France is $202.5 Million by 2035. **Q: What is the expected CAGR for the France vasomotor symptoms market during the forecast period 2025 - 2035?** A: The expected CAGR for the France vasomotor symptoms market during the forecast period 2025 - 2035 is 6.58%. **Q: Which companies are considered key players in the France vasomotor symptoms market?** A: Key players in the France vasomotor symptoms market include Pfizer Inc, Bristol-Myers Squibb Company, AbbVie Inc, Mylan N.V., Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche Ltd, AstraZeneca PLC, and Novartis AG. **Q: What are the two main types of products in the France vasomotor symptoms market?** A: The two main types of products in the France vasomotor symptoms market are hormonal and non-hormonal treatments. **Q: What were the valuations for hormonal and non-hormonal segments in 2024?** A: In 2024, the hormonal segment was valued at $40.2 Million, while the non-hormonal segment was valued at $60.3 Million. **Q: How do hospital pharmacies compare to retail pharmacies in terms of market valuation for vasomotor symptoms?** A: In 2024, hospital pharmacies were valued at $30.0 Million, whereas retail pharmacies had a higher valuation of $40.5 Million. **Q: What is the projected growth for online stores in the France vasomotor symptoms market by 2035?** A: The valuation for online stores in the France vasomotor symptoms market is projected to reach $62.5 Million by 2035. **Q: What is the significance of the distribution channels in the France vasomotor symptoms market?** A: Distribution channels such as hospital pharmacies, retail pharmacies, and online stores play a crucial role in the accessibility and availability of vasomotor symptom treatments. **Q: How does the market for non-hormonal treatments compare to hormonal treatments in terms of growth potential?** A: The non-hormonal treatments segment, valued at $121.5 Million by 2035, indicates a higher growth potential compared to the hormonal segment, which is projected to reach $81.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/france-vasomotor-symptoms-market-51751*